Naoto Ueno, Director at University of Hawai’i Cancer Center, shared on X:
“A very interesting paper.
The issue goes beyond investigator-initiated trials and hospital self-regulation. High-risk studies need independent review and ongoing safety monitoring.
This includes oncology studies. I would like to see more phase III oncology trials in China conducted as international studies.
Involving investigators and patients from other countries would create opportunities for collaboration and help us understand whether the results apply to broader populations.
That collaboration needs to include shared responsibility for study design, access to data, and transparent reporting of both benefits and harms. These are standards we should expect of trials in every country.”
Title: Lessons from recent investigator-initiated trials of gene-editing therapies in China
Authors: Li Du, Kalina Kamenova, Zhangyu Wang, Meng Wang, Yujuan Li, Ruipeng Lei, Xi Zhang
You can also read: